BioCryst Reports Q3 2026 Results, Reaches Profitability
BioCryst reported total net revenue of $180.3 million and operating profit of $53.3 million. The company also received FDA approval for the 150 mg pellet formulation of ORLADEYO and raised full-year revenue guidance to $715 million to $730 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed